ArticleCancer science2018
c-Src inhibitor selectively inhibits triple-negative breast cancer overexpressed Vimentin in vitro and in vivo.
Article in Cancer science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- Src and Abl as Therapeutic Targets in Lung Cancer: Opportunities for Drug Repurposing.Pharmaceuticals (Basel, Switzerland) · 2025Review
- TYMS Knockdown Suppresses Cells Proliferation, Promotes Ferroptosis via Inhibits PI3K/Akt/mTOR Signaling Pathway Activation in Triple Negative Breast Cancer.Cell biochemistry and biophysics · 2024Article
- Methoxyhispolon Methyl Ether, a Hispolon Analog, Thwarts the SRC/STAT3/BCL-2 Axis to Provoke Human Triple-Negative Breast Cancer Cell Apoptosis In Vitro.Biomedicines · 2023Article
- Anoikis resistance--protagonists of breast cancer cells survive and metastasize after ECM detachment.Cell communication and signaling : CCS · 2023Review
- Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer.Biomolecules · 2023Review
- Transcriptomic Analysis of Subtype-Specific Tyrosine Kinases as Triple Negative Breast Cancer Biomarkers.Cancers · 2023Article
- SRC kinase-mediated signaling pathways and targeted therapies in breast cancer.Breast cancer research : BCR · 2022Review
- Circular RNA hsa_circ_0002360 Promotes Proliferation and Invasion and Inhibits Oxidative Stress in Gastric Cancer by Sponging miR-629-3p and Regulating the PDLIM4 Expression.Oxidative medicine and cellular longevity · 2022Article
- Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Gallic acid suppresses colon cancer proliferation by inhibiting SRC and EGFR phosphorylation.Experimental and therapeutic medicine · 2021Article
- MiRNA-mediated EMT and CSCs in cancer chemoresistance.Experimental hematology & oncology · 2021Review
- Article
- Is vimentin a potential prognostic factor for patients with triple-negative breast cancer?Journal of cancer research and clinical oncology · 2020Article
- Review
- Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned so Far.Cancers · 2020Review
- PDLIM4/RIL-mediated regulation of Src and malignant properties of breast cancer cells.Oncotarget · 2020Article
- The LQB-223 Compound Modulates Antiapoptotic Proteins and Impairs Breast Cancer Cell Growth and Migration.International journal of molecular sciences · 2019Article
- Diosgenin inhibits the epithelial-mesenchymal transition initiation in osteosarcoma cells via the p38MAPK signaling pathway.Oncology letters · 2019Article
- Emerging Roles of 5-Lipoxygenase Phosphorylation in Inflammation and Cell Death.Oxidative medicine and cellular longevity · 2019Review
- c-Src inhibitor selectively inhibits triple-negative breast cancer overexpressed Vimentin in vitro and in vivo.Cancer science · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncogene c-Src has been found to be a potential target for the treatment of triple-negative breast cancer (TNBC). However, the therapeutic effects of the c-Src inhibitor on TNBC patients are controversial compared to those on cell lines. The molecular mechanisms of the inhibitory effects of the c-Src inhibitor on TNBC remain unclear. Herein, we showed that a specific c-Src inhibitor, PP2, was effective in inhibiting phosphorylation of c-Src in 4 cell lines: T-47D, SK-BR-3, SUM1315MO2, and MDA-MB-231, regardless of hormone receptors and human epidermal growth factor receptor 2 (HER2) expression levels. Giving PP2 preferentially reduced the S phase of cell cycles and inhibited colony formation in SUM1315MO2 and MDA-MB-231, but not in SK-BR-3 and T-47D cells. Furthermore, PP2 effectively blocked cell migration/invasion and epithelial-mesenchymal transition (EMT) in TNBC cell lines, SUM1315MO2 and MDA-MB-231. An EMT biomarker, vimentin, was highly expressed in 2 TNBC cell lines when they were compared with SK-BR-3 and T-47D cells. Further depletion of vimentin by shRNA remarkably attenuated the inhibitory effects of the c-Src inhibitor on TNBC cells in vitro and in vivo, indicating a crucial action of vimentin to affect the function of c-Src in TNBC. This study provides an important rationale for the clinic to precisely select TNBC patients who would benefit from c-Src inhibitor treatment. This finding suggests that traditional markers for TNBC are not sufficient to precisely define this aggressive type of cancer. Vimentin is identified as an important biomarker to enable categorization of TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.